Dr. Hu’s research interests include drug development and translational cancer pharmacology, and her current projects are focused on the development of transport modulators that could be used in conjunction with neurotoxic chemotherapy. The overall goal of her research is to evaluate the role of solute carriers in cancer drug-induced toxicity profiles, in particular peripheral neuropathy. In addition, she aims to identify chemical inhibitors of critical transporters, and explore novel strategies to ameliorate the incidence and severity of debilitating side effects of cancer drugs.
- PhD, Pharmaceutical Sciences, West Virginia University
- Dean's Innovative Research Award, 2019
- Chen M, Hu S, Li Y, Gibson AA, Fu Q, Baker SD, Sparreboom A. Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions. Drug Metab Dispos. 2020 May;48(5):419-425.
- Huang KM, Uddin ME, DiGiacomo D, Lustberg MB, Hu S, Sparreboom A. Role of SLC transporters in toxicity induced by anticancer drugs. Expert Opin Drug Metab Toxicol. 2020 Jun;16(6):493-506.
- Stage TB, Hu S, Sparreboom A, Kroetz DL. Role for Drug Transporters in Chemotherapy-Induced Peripheral Neuropathy. Clin Transl Sci. 2020 Nov 3.
- Anderson JT, Huang KM, Lustberg MB, Sparreboom A, Hu S. Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions. Rev Physiol Biochem Pharmacol. 2020 Aug 7.
- Hu S, Huang KM, Adams EJ, Loprinzi CL, and Maryam Lustberg MB. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res. 2019 May 23.
- View all journal articles